Daniel L. Baker

7.1k total citations · 1 hit paper
88 papers, 5.7k citations indexed

About

Daniel L. Baker is a scholar working on Molecular Biology, Rheumatology and Physiology. According to data from OpenAlex, Daniel L. Baker has authored 88 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 19 papers in Rheumatology and 12 papers in Physiology. Recurrent topics in Daniel L. Baker's work include Sphingolipid Metabolism and Signaling (37 papers), Rheumatoid Arthritis Research and Therapies (18 papers) and Receptor Mechanisms and Signaling (16 papers). Daniel L. Baker is often cited by papers focused on Sphingolipid Metabolism and Signaling (37 papers), Rheumatoid Arthritis Research and Therapies (18 papers) and Receptor Mechanisms and Signaling (16 papers). Daniel L. Baker collaborates with scholars based in United States, Japan and Belgium. Daniel L. Baker's co-authors include Abby L. Parrill, Gábor Tigyi, E. William St. Clair, Joan M. Bathon, Gábor Tigyi, Désirée van der Heijde, Paul Emery, Josef S Smolen, Ravinder N. Maini and Edward Keystone and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Circulation.

In The Last Decade

Daniel L. Baker

86 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

2004 940 citations E. William St. Clair, Ravinder N. Maini et al. Arthritis & Rheumatism profile →

Peers

Countries citing papers authored by Daniel L. Baker

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Baker more than expected).

Fields of papers citing papers by Daniel L. Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Baker. The network helps show where Daniel L. Baker may publish in the future.

Co-authorship network of co-authors of Daniel L. Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Baker. A scholar is included among the top collaborators of Daniel L. Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Baker. Daniel L. Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In vitro evaluation of loaded chitosan membranes for pain relief and infection prevention 2021 ·Journal of Biomedical Materials Research Part B Applied Biomaterials ·(unknown), Joel D. Bumgardner, Tomoko Fujiwara, Daniel L. Baker, Jessica Amber Jennings	11
2	Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes: Impact of ligand type and receptor activation state 2021 ·Journal of Molecular Graphics and Modelling ·(unknown), Abby L. Parrill, Daniel L. Baker	7
3	Benchmarking GPCR homology model template selection in combination with de novo loop generation 2020 ·Journal of Computer-Aided Molecular Design ·(unknown), (unknown), (unknown), (unknown), Judith A. Cole, Daniel L. Baker, Abby L. Parrill	5
4	A benchmark study of loop modeling methods applied to G protein-coupled receptors 2019 ·Journal of Computer-Aided Molecular Design ·(unknown), Daniel L. Baker, Judith A. Cole, Abby L. Parrill	16
5	G protein-coupled receptors: the evolution of structural insight 2017 ·AIMS Biophysics ·(unknown), Daniel L. Baker, Abby L. Parrill	58
6	The effects of structural damage on functional disability in psoriatic arthritis 2017 ·Annals of the Rheumatic Diseases ·Andreas Kerschbaumer, Daniel L. Baker, Josef S Smolen, Daniel Aletaha	37
7	Multi-platform comparison of ten commercial master mixes for probe-based real-time polymerase chain reaction detection of bioterrorism threat agents for surge preparedness 2012 ·Forensic Science International ·Gregory S. Buzard, Daniel L. Baker, Mark Wolcott, David Norwood, Leslie A. Dauphin	32
8	Electrocatalytic and Photocatalytic Hydrogen Production in Aqueous Solution by a Molecular Cobalt Complex 2012 ·Angewandte Chemie International Edition ·W.M. Singh, (unknown), (unknown), Shiliang Tian, (unknown), Hongyu Zhou, Nathan J. DeYonker, Truc Chi T. Pham, John C. Bollinger, Daniel L. Baker, Bing Yan, Charles Edwin Webster, Xuan Zhao	295
9	Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab 2011 ·The Journal of Rheumatology ·Peter C. Taylor, Christopher T. Ritchlin, Alan M. Mendelsohn, Daniel L. Baker, Lilianne Kim, Zhenhua Xu, M. Mack, Joel M. Kremer	10
10	Benzyl and Naphthalene Methylphosphonic Acid Inhibitors of Autotaxin with Anti‐invasive and Anti‐metastatic Activity 2011 ·ChemMedChem ·(unknown), Renukadevi Patil, Jianxiong Liu, Yaohong Wang, (unknown), Yuko Fujiwara, James I. Fells, (unknown), (unknown), Charles R. Yates, (unknown), Nattapon Panupinthu, (unknown), Daniel L. Baker, Abby L. Parrill, Gordon B. Mills, Gábor Tigyi, Duane D. Miller	51
11	Phospholipase D2-Dependent Inhibition of the Nuclear Hormone Receptor PPARγ by Cyclic Phosphatidic Acid 2010 ·Molecular Cell ·Tamotsu Tsukahara, Ryoko Tsukahara, Yuko Fujiwara, Junming Yue, Yunhui Cheng, Huazhang Guo, (unknown), Chunxiang Zhang, Louisa Balázs, Fabio Re, Guangwei Du, Michael A. Frohman, Daniel L. Baker, Abby L. Parrill, Ayako Uchiyama, Tetsuyuki Kobayashi, Kimiko Murakami‐Murofushi, Gábor Tigyi	101
12	Autotaxin structure–activity relationships revealed through lysophosphatidylcholine analogs 2009 ·Bioorganic & Medicinal Chemistry ·E. Jeffrey North, Daniel A. Osborne, Peter K. Bridson, Daniel L. Baker, Abby L. Parrill	23
13	Characterization of non-lipid autotaxin inhibitors 2009 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), (unknown), Truc Chi T. Pham, Abby L. Parrill, Daniel L. Baker	20
14	Infliximab treatment maintains employability in patients with early rheumatoid arthritis 2006 ·Arthritis & Rheumatism ·Josef S Smolen, Chenglong Han, Désirée van der Heijde, Paul Emery, Joan M. Bathon, Edward Keystone, Joachim R. Kalden, Michael Schiff, Mohan Bala, Daniel L. Baker, John Han, Ravinder N. Maini, E. William St. Clair	90
15	Identification of Residues Responsible for Ligand Recognition and Regioisomeric Selectivity of Lysophosphatidic Acid Receptors Expressed in Mammalian Cells 2005 ·Journal of Biological Chemistry ·Yuko Fujiwara, (unknown), Akira Tokumura, Daniel L. Baker, Kimiko Murakami‐Murofushi, Abby L. Parrill, Gábor Tigyi	77
16	Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Veeresa Gududuru, Kui Zeng, Ryoko Tsukahara, Natalia Makarova, Yuko Fujiwara, (unknown), Daniel L. Baker, Gábor Tigyi, Duane D. Miller	34
17	Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor γ 2005 ·Journal of Biological Chemistry ·Tamotsu Tsukahara, Ryoko Tsukahara, Satoshi Yasuda, Natalia Makarova, William J. Valentine, Patrick Allison, Hongbin Yuan, Daniel L. Baker, Zaiguo Li, Robert Bittman, Abby L. Parrill, Gábor Tigyi	74
18	Şiddetli plak tipi psoriazisde infliksimab indüksiyon tedavisi: Randomize, çift-kör, plasebo kontrollü çalışma 2004 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Robert J. Evans, Shu Li, (unknown), Cynthia Guzzo, Daniel L. Baker, Mohan Bala, Colleen Marano, (unknown), (unknown), (unknown), (unknown), (unknown)	1
19	Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial 2004 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Robert J. Evans, Shu Li, Lisa T. Dooley, Cynthia Guzzo, Daniel L. Baker, Mohan Bala, Colleen Marano, Alan Menter	456
20	Molecular basis for lysophosphatidic acid receptor antagonist selectivity 2002 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·(unknown), Debra L. Bautista, David J. Fischer, Kazuaki Yokoyama, Nóra Nusser, Tamás Virág, De-an Wang, Daniel L. Baker, Gábor Tigyi, Abby L. Parrill	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact